Results 221 to 230 of about 120,548,321 (260)
Some of the next articles are maybe not open access.
Botulinum Toxin Type B (Myobloc)
Dermatologic Surgery, 2003Myobloc, known as Neurobloc in Europe, is a member of the botulinum toxin family. It has been used for a myriad of problems since its approval in the United States in December 2000. It is currently not approved for cosmetic use but has been used for this purpose. This article reviews what is currently known about botulinum toxin type B and its efficacy
Leslie, Baumann, Laura, Black
openaire +2 more sources
Botulinum Toxin Type A in Dental Medicine
Journal of Dental Research, 2019Botulinum toxins (BoNTs) are a product of the bacteria Clostridium botulinum. By entering nerve endings, they cleave and inactivate SNARE proteins, which are essential for neurotransmitter release. Prevention of acetylcholine release at the neuromuscular junction causes long-lasting and potentially fatal flaccid paralysis—a major feature of botulism ...
V.R.M. Muñoz Lora +3 more
openaire +2 more sources
Pharmacology and immunology of botulinum toxin type A
Clinics in Dermatology, 2003The utility of botulinum neurotoxins as therapeutic and esthetic agents depends on their ability to inhibit neurotransmitter release from selected neurons, remain localized at the site of injection, and evade the body's immunologic defenses. The clinical correlates of these actions, respectively, are efficacy, safety, and a low rate of antibody ...
openaire +2 more sources
Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy
Movement Disorders, 2002AbstractIn some patients, therapy with botulinum toxin type A (BT‐A) becomes ineffective due to formation of antibodies (BT‐A‐AB). The time course of BT‐A‐AB titres after cessation of BT‐A therapy was quantitatively studied to determine whether and when they might drop.
Dirk, Dressler, Hans, Bigalke
openaire +2 more sources
Observations on the Type A Toxin of Clostridium botulinum
Nature, 1951THE recent communication by Wentzel, Sterne and Polson1 makes it desirable to record some supplementary observations made in the chemical investigation of a number of toxins, especially that produced by Clostridium botulinum Type A. In the present experiments, the toxicity was determined by intraperitoneal injection into white mice of 20 gm. weight.
openaire +2 more sources
Journal of the American Academy of Dermatology, 2005
Alastair, Carruthers, Jean, Carruthers
openaire +2 more sources
Alastair, Carruthers, Jean, Carruthers
openaire +2 more sources
Botulinum toxin type A for the treatment of migraine
Expert Opinion on Pharmacotherapy, 2006Migraine is a common and debilitating disorder that often requires prophylactic therapy, particularly for those migraine patients who meet the diagnostic criteria for chronic daily headache (chronic migraine). Existing prophylactic treatments for migraine are inadequate for many patients due to their modest efficacy and/or systemic side effects ...
openaire +2 more sources
[Botulinum toxin Type A. Indications and results].
Revista de neurologia, 2003Since introduction for clinical in the 80s, the botulinum toxin type A is being used with effectiveness in the treatment of different disorders that goes with exaggerated muscular activity. Numerous studies have been demonstrated useful for focal treatment of spasticity.Some indications of the botulinum toxin type A for the treatment of the cerebral ...
Póo P +5 more
openaire +2 more sources